Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 21, 2023

Primary Completion Date

July 15, 2025

Study Completion Date

December 15, 2026

Conditions

Hereditary Red Blood Cell Disorder (Disorder)

Interventions

DRUG

Mitapivat sulfate

Subjects enrolled Maximum dose: will receive Mitapivat during 56 weeks Starting dose: 50 mg BD Maximum dose: 100 mg BD

Trial Locations (2)

Copenhagen University Hospital - Rigshospitalet, Copenhagen

Department of Internal Medicine, University Medical Center Utrecht, Utrecht

All Listed Sponsors

lead

EuroBloodNet Association

OTHER